RT Journal Article
SR Electronic
T1 Prevalence of Cardiometabolic Disease Risk Factors in People living with HIV Initiating Anti-retroviral Therapy at a High-Volume HIV Clinic in Kampala, Uganda
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2023.03.18.23287437
DO 10.1101/2023.03.18.23287437
A1 Amutuhaire, Willington
A1 Mulindwa, Frank
A1 Castelnuovo, Barbara
A1 Brusselaers, Nele
A1 Schwarz, Jean-Marc
A1 Edrisa, Mutebi
A1 Dujanga, Simon
A1 Salata, Robert A.
A1 Yendewa, George A.
YR 2023
UL http://medrxiv.org/content/early/2023/03/19/2023.03.18.23287437.abstract
AB Background Cardiometabolic diseases are a leading cause of HIV-related morbidity and mortality, yet routine screening is not undertaken in high burden countries. We aimed to assess the prevalence and risk factors of the metabolic syndrome (MetS) and its components in adult Ugandan people living with HIV (PLHIV) initiating dolutegravir-based antiretroviral therapy (ART).Methods We analyzed baseline data of PLHIV aged ≥ 18 years enrolled in the GLUMED (Glucose metabolism changes in Ugandan HIV patients on Dolutegravir) Study from January to October 2021. MetS was defined as having 3 or more of the following: abdominal obesity, hypertension (HTN), elevated fasting glucose, elevated triglycerides and low high-density lipoprotein cholesterol. Multiple logistic regression was used to assess associations between potential risk factors and MetS and its components.Results 309 PLHIV were analyzed (100% ART-naive, 59.2% female, median age 31 years and median CD4 count 318 cells/mm3). The prevalence of MetS was 13.9%. The most common cardiometabolic condition was dyslipidemia (93.6%), followed by abdominal obesity (34.0%), hyperglycemia (18.4%), and HTN (8.1%). In adjusted analysis, MetS was associated with age > 40 years (odds ratio 3.33, 95% confidence interval 1.45-7.67) and CD4 count > 200 cells/mm3 (3.79, 1.23-11.63). HTN was associated with age > 40 years (2.96, 1.32-6.64), and dyslipidemia was associated with urban residence (4.99, 1.35-18.53).Conclusion Cardiometabolic risk factors were common in this young Ugandan cohort of PLHIV initiating dolutegravir-based ART, underscoring the need for programmatic implementation of surveillance and management of comorbidities in Uganda and similar settings.Key points In Ugandan HIV patients initiating antiretroviral treatment, the prevalence of cardiometabolic risk factors was substantial: metabolic syndrome 13.9%, dyslipidemia 93.6%, abdominal obesity 34.0%, hyperglycemia 18.4%, and hypertension 8.1%. This highlights the need for early screening and management of comorbidities.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThe study received funding support from NIH-Fogarty University of California (UCSF) Global Health Fellowship Program, grant number: 2D43TW009343-06 (F.M., J-M.S.), the National Institutes of Health, UCSF-Gladstone Center for AIDS Research, grant number: P30AI027763 (F.M., J-M.S.) and the Fogarty International Center of the National Institutes of Health, Award Number D43TW009771 (B.C.). Additional funding were provided through the Roe Green Center for Travel Medicine and Global Health/University Hospitals Cleveland Medical Center (W.A., G.A.Y.).Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:Ethical approval to perform the study was obtained from The AIDS Support Organization (TASO) Institutional Review Board (registration number: TASOREC/051/2020-UG-REC-009) and the Uganda National Council for Science and Technology (Registration number: HS1032ES). All participants signed informed consent prior to enrolment in the study.I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.YesAll data produced in the present work are contained in the manuscript